Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.47 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | DNM1L | O00429 | 2/20 | 0.32 |
| ▸ | HPGDS | O60760 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19850450 | 0.88 | AOC3 (0.55) | SLC6A3AOC3DRD2HTR2AHPGDS | |
| Hydrochloric Acid SCHEMBL7181165 | 0.78 | SLC6A3 (0.47) | SLC6A3AOC3DRD2HTR2AALDH1A1 | |
| SCHEMBL3866723 | 0.77 | OGA (0.38) | SLC6A3AOC3DRD2HTR2AALDH1A1 | |
| SCHEMBL16260484 | 0.76 | SLC6A3 (0.43) | SLC6A3AOC3DRD2HTR2ADNM1L | |
| SCHEMBL7180222 | 0.76 | SLC6A3 (0.43) | SLC6A3AOC3DRD2HTR2ADNM1L | |
| SCHEMBL9265855 | 0.73 | SLC6A3 (0.43) | SLC6A3AOC3DRD2HTR2ADNM1L | |
| SCHEMBL9065445 | 0.73 | DRD2 (0.43) | SLC6A3AOC3DRD2HTR2ADNM1L | |
| SCHEMBL9264679 | 0.73 | SLC6A3 (0.41) | SLC6A3AOC3DRD2HTR2ADNM1L | |
| SCHEMBL17591448 | 0.72 | — | — | |
| SCHEMBL15356505 | 0.72 | DRD2 (0.45) | SLC6A3AOC3DRD2HTR2ADNM1L |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9090599-B2 | Heteroarylmethyl amides | HOFFMANN-LA ROCHE INC. (US) | 2015-07-28 | — | — | US | claimed |
| US-20140194436-A1 | HETEROARYLMETHYL AMIDES | HOFFMANN-LA ROCHE INC. (US) | 2014-07-10 | — | — | US | claimed |
| EP-2613785-A1 | HETEROARYLMETHYL AMIDES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-07-17 | — | — | EP | claimed |
| CN-103118680-A | Heteroarylmethyl amides | HOFFMANN LA ROCHE | 2013-05-22 | — | — | CN | claimed |
| WO-2012032018-A1 | HETEROARYLMETHYL AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | WO | claimed |
| EP-2755952-B1 | 5-CYCLOALKYL- OR 5-HETEROCYCLYL-NICOTINAMIDES | HOFFMANN LA ROCHE (CH) | 2016-03-30 | — | — | EP | disclosed |
| EP-2613785-B1 | HETEROARYLMETHYL AMIDES | HOFFMANN LA ROCHE (CH) | 2015-07-29 | — | — | EP | disclosed |
| US-9090599-B2 | Heteroarylmethyl amides | HOFFMANN-LA ROCHE INC. (US) | 2015-07-28 | — | — | US | disclosed |
| EP-2755952-A1 | 5-CYCLOALKYL- OR 5-HETEROCYCLYL-NICOTINAMIDES | F.HOFFMANN-LA ROCHE AG (CH) | 2014-07-23 | — | — | EP | disclosed |
| US-20140194436-A1 | HETEROARYLMETHYL AMIDES | HOFFMANN-LA ROCHE INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-8729105-B2 | Heteroarylmethyl amides | HOFFMANN LA-ROCHE INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-8629166-B2 | 5-cycloalkyl- or 5-heterocyclyl-nicotinamides | HOFFMANN-LA ROCHE INC. (US) | 2014-01-14 | — | — | US | disclosed |
| EP-2613785-A1 | HETEROARYLMETHYL AMIDES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-07-17 | — | — | EP | disclosed |
| CN-103118680-A | Heteroarylmethyl amides | HOFFMANN LA ROCHE | 2013-05-22 | — | — | CN | disclosed |
| WO-2013037721-A1 | 5-CYCLOALKYL- OR 5-HETEROCYCLYL-NICOTINAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-21 | — | — | WO | disclosed |
| US-20130065907-A1 | 5-CYCLOALKYL- OR 5-HETEROCYCLYL-NICOTINAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-14 | — | — | US | disclosed |
| US-20120065212-A1 | HETEROARYLMETHYL AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | US | disclosed |
| WO-2012032018-A1 | HETEROARYLMETHYL AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140194436-A1 | HETEROARYLMETHYL AMIDES | APOB, LDLR, HMGCR | SLC6A3 3954/4885AOC3 1654/4885DRD2 2766/4885 |
| US-20130065907-A1 | 5-CYCLOALKYL- OR 5-HETEROCYCLYL-NICOTINAMIDES | NNT, APOB, LDLR | SLC6A3 3858/4885AOC3 1721/4885DRD2 2824/4885 |
| US-20120065212-A1 | HETEROARYLMETHYL AMIDES | APOB, LDLR, HMGCR | SLC6A3 3954/4885AOC3 1654/4885DRD2 2766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.